Affymax, Inc.
Affymax® Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide™ Regardless of Patient Baseline Renal Function
Published in Hospital Business Week, June 14th, 2009
Affymax, Inc. (Nasdaq:AFFY) announced data from a post hoc analysis of 120 patients in a Phase 2 clinical trial of Hematide™ in non-dialysis chronic kidney disease (CKD) patients. The data suggest that there is no major impact of baseline renal function as measured by Estimated Glomerular Filtration Rate (eGFR) on the monthly Hematide dose required to increase and maintain hemoglobin (Hgb) values within target range in non-dialysis CKD patients. The data were presented by Iain C. Macdougall, M.D. at the World Congress of Nephrology meeting being held in Milan, Italy.
“As Hematide is partially excreted by the kidneys, it was imperative to evaluate whether renal function...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
More Articles from Hospital Business Week
- 4SC AG
4SC presents Phase I data on its histone deacetylase HDAC inhibitor 4SC-201 at ASCO - ACS
ACS Develops E-prescribing Capability for Alabama Medicaid - Allscripts
Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record - Alpha Systems
Alpha Systems Best in KLAS - American Jewish Committee
AJC: Libya is Responsible for Death of Human Rights Activist - Ballast Nedam Nv
Erasmus MC Awards Major Hospital Contract to BAM-Ballast Nedam Joint Venture - More from this issue of Hospital Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
